Clay Siegall’s role in Cancer Treatment

National Cancer Institute states that about 40 percent of women and men in the U.S will at one point of their life be diagnosed with some form of cancer. Over 600,000 people lost their cancer battles in U.S alone. Given these shocking statistics, it is obvious to feel like there is little that is being done about this terrible disease, but that is not the case. Biotech firms like the Seattle genetics are pushing the cancer treatment and research boundaries with men like Clay Siegall at their top. Their commitment enables them to make significant progress in the field.

Dr.Clay Siegall is the CEO and founder of Seattle Genetics, a biotech firm based in Seattle that specializes in targeted therapy drugs development for the types of diseases that have not seen any substantial mortality improvements in decades. He holds a B.S in Zoology from the University of Maryland and a genetics Ph. D. from Gorge Washington University.

Since he established the Seattle Genetic back in 1998, Dr. Siegall has led his firm to great heights in the targeted therapy industry through the development of the first FDA-approved conjugate antibody drug, which currently has multiple approved indications. Clay has also developed a robust pipeline of more than 20 drugs and some strategic partnerships with manufacturers of drugs including Genentech, Bayer, Pfizer, and others.

Seattle Genetics under the leadership of Dr. Siegall has grown from a small startup with just a few researchers to a great power player in the research space of cancer. Mr. Siegall has big plans for the future of the company. With the expanding list of the drugs in its development pipeline and an ever increasing number of prospective indications for the existing drug portfolio of the company, the firm is in an excellent position to move with authority into the 21st-century industry in drug development.

Dr. Siegall also worked with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. Clay is one of the Boards of Trustees of Ultrageny Pharmaceutical, Washington Round table, and Alder Bio Pharmaceuticals. Dr. Siegall has been a recipient of several awards which includes University of Maryland Alumnus of the year for Math, Natural Sciences and Computer in 2013, and the Pacific North Ernst and Young Entrepreneur of the year in 2012. He has written seventy publications and holds 15 patents.